These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
331 related items for PubMed ID: 1979813
1. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. Oberlender R, Nichols DE. J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813 [Abstract] [Full Text] [Related]
2. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline. Callahan PM, Appel JB. J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488 [Abstract] [Full Text] [Related]
3. Drug discrimination studies with MDMA and amphetamine. Oberlender R, Nichols DE. Psychopharmacology (Berl); 1988 Sep; 95(1):71-6. PubMed ID: 2898791 [Abstract] [Full Text] [Related]
4. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB. Behav Pharmacol; 1995 Apr; 6(3):263-275. PubMed ID: 11224335 [Abstract] [Full Text] [Related]
5. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination. Baker LE, Taylor MM. Pharmacol Biochem Behav; 1997 Aug; 57(4):737-48. PubMed ID: 9259001 [Abstract] [Full Text] [Related]
6. N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Aerts LA, Mallaret M, Rigter H. Addict Biol; 2000 Jul 01; 5(3):269-82. PubMed ID: 20575841 [Abstract] [Full Text] [Related]
7. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Marona-Lewicka D, Nichols DE. Eur J Pharmacol; 1994 Jun 02; 258(1-2):1-13. PubMed ID: 7925587 [Abstract] [Full Text] [Related]
8. Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Nakagawa Y, Suzuki T, Tayama S, Ishii H, Ogata A. Arch Toxicol; 2009 Jan 02; 83(1):69-80. PubMed ID: 18553070 [Abstract] [Full Text] [Related]
9. The effects of MDMA and other methylenedioxy-substituted phenylalkylamines on the structure of rat locomotor activity. Paulus MP, Geyer MA. Neuropsychopharmacology; 1992 Aug 02; 7(1):15-31. PubMed ID: 1355968 [Abstract] [Full Text] [Related]
13. Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodents. Gatch MB, Dolan SB, Forster MJ. Behav Pharmacol; 2016 Sep 02; 27(6):497-505. PubMed ID: 27028902 [Abstract] [Full Text] [Related]
14. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Johanson CE, Kilbey M, Gatchalian K, Tancer M. Drug Alcohol Depend; 2006 Jan 04; 81(1):27-36. PubMed ID: 15975736 [Abstract] [Full Text] [Related]
15. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA). Johnson MP, Frescas SP, Oberlender R, Nichols DE. J Med Chem; 1991 May 04; 34(5):1662-8. PubMed ID: 1674539 [Abstract] [Full Text] [Related]
16. Differential substitution for the discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and methylphenidate in rats. Mori T, Uzawa N, Kazawa H, Watanabe H, Mochizuki A, Shibasaki M, Yoshizawa K, Higashiyama K, Suzuki T. J Pharmacol Exp Ther; 2014 Aug 04; 350(2):403-11. PubMed ID: 24917544 [Abstract] [Full Text] [Related]